Atrion Co. (NASDAQ:ATRI) Announces Quarterly Dividend of $1.55

Atrion Co. (NASDAQ:ATRI) announced a quarterly dividend on Monday, August 19th, Zacks reports. Investors of record on Monday, September 16th will be paid a dividend of 1.55 per share by the medical instruments supplier on Monday, September 30th. This represents a $6.20 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend is Friday, September 13th. This is an increase from Atrion’s previous quarterly dividend of $1.35.

Atrion has increased its dividend by an average of 15.6% per year over the last three years and has raised its dividend every year for the last 16 years.

Atrion stock traded up $0.75 during trading on Wednesday, reaching $786.45. 469 shares of the company’s stock were exchanged, compared to its average volume of 15,000. The company’s 50-day moving average is $771.74 and its two-hundred day moving average is $832.81. Atrion has a 52-week low of $624.00 and a 52-week high of $948.03. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of 38.32 and a beta of 0.27.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $5.18 earnings per share for the quarter. Atrion had a net margin of 23.14% and a return on equity of 16.79%. The firm had revenue of $40.10 million during the quarter.

In other Atrion news, Director Ronald Nicholas Spaulding sold 170 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $903.00, for a total value of $153,510.00. Following the transaction, the director now owns 2,158 shares in the company, valued at approximately $1,948,674. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 22.07% of the company’s stock.

A number of brokerages have commented on ATRI. ValuEngine lowered shares of Atrion from a “buy” rating to a “hold” rating in a report on Friday, July 26th. BidaskClub upgraded shares of Atrion from a “strong sell” rating to a “sell” rating in a report on Saturday, August 3rd.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Further Reading: What is the CBOE Russell 2000® Volatility Index?

Dividend History for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with's FREE daily email newsletter.